Pharmacotherapeutic Decisions In Menopausal Women With Cardiovascular Risk

Bibliography

• American Heart Association. 2006 Heart and stroke statistical update. Circulation 113, 85–151 (2006).
   Google Scholar
• The writing group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288, 321–333 (2002).
   Google Scholar
• Manson, JE, Hsia J, Johnson KC et al.: Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349, 523–534 (2003).
   Google Scholar
• The writing group for the Women’s Health Initiative Investigators. Effects of Conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291, 1701–1712 (2004).
   Google Scholar
• Hsia J, Langer RD, Manson JE et al.: Conjugated equine estrogens and coronary heart disease. The Women’s Health Initiative. Arch. Intern. Med. 166, 357–365 (2006).
   Google Scholar
• Hulley S, Grady D, Bush T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 280, 605–613 (1998).
   Google Scholar
• Barrett-Connor E, Mosca L, Collins P et al.: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125–137 (2006).
   Google Scholar
• Lloyd-Jones D, O’Donnell CJ, D’Agostino RB et al.: Applicability of cholesterol-lowering primary prevention trials to a general population. The Framingham Heart Study. Arch. Intern. Med. 161, 949–954 (2001).
   Google Scholar
• Demonstrates the incidence of coronary heart disease associated with triglyceride (TG) in women.
   Google Scholar
• Collins P: Clinical cardiovascular studies of hormone replacement therapy. Am. J. Cardiol. 90(Suppl.), F30–F34 (2002).
   Google Scholar
• Dayspring T, Qub Y, Keech C: Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia. Metab. Clin. Exp. 55, 972–979 (2006).
   Google Scholar
• Mosca L, Banka CL, Benjamin EJ et al.: For the Expert Panel/Writing Group. Evidenced-based guidelines for cardiovascular disease prevention in women. J. Am. Coll. Cardiol. 49, 1230–1250 (2007).
   Google Scholar
• Manson JE, Hsia J, Johnson KC et al.: For the Women’s Health Initiative Investigators: estrogen and progestin for coronary heart disease. N. Engl. J Med. 349, 523–534 (2003).
   Google Scholar
• Hodis H, Mack W, Lobo R et al.: Estrogen in the prevention of atherosclerosis. Ann. Int. Med. 135, 939–953 (2001).
   Google Scholar
• Hodis HN, Mack WJ, Azen SP et al.: For the Women’s Estrogen–Progestin Lipid- Lowering Hormone Atherosclerosis Regression Trial: hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N. Engl. J. Med. 349, 535–545 (2003).
   Google Scholar
• Lobo RA, Bush T, Carr BR, Pickar JH: Effects of lower doses of conjugatedequine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil. Steril. 76, 13–24 (2001).
   Google Scholar
• Mendelsohn ME, Karas RH: Molecular and cellular basis of cardiovascular gender differences. Science 308, 1583–1587 (2005).
   Google Scholar
• Ouyang P, Michos ED, Karas RH: Hormone replacement therapy and the cardiovascular system. Lessons learned and unanswered questions. J. Am. Coll. Cardiol. 47, 1741–1753 (2006).
   Google Scholar
• Grodstein F, Mason JE, Stampfer MJ: Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J. Womens Hist. 15(1), 35–44 (2006).
   Google Scholar
• Intriguing analysis of the timing of estrogen therapy and cardiovascular benefit.
   Google Scholar
• Harmon SM, Brinton EA, Cedars M et al.: KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8, 3–12 (2005).
   Google Scholar
• Barter PJ, Ballantyne CM, Carmena R et al.: Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten country panel. J. Intern. Med. 259, 247–258 (2006).
   Google Scholar
• Very important consensus paper on replacing lipid measurements with apolipoprotein measurements.
   Google Scholar
• Kuller L, Arnold A, Tracy R et al.: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 22, 1175–1180 (2002).
   Google Scholar
• Blake GJ, Otvos JD, Rifai N et al.: Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 106, 1930–1937 (2002).
   Google Scholar
• Cromwell WC, Otvos JD: Low-density lipoprotein particle number and risk for cardiovascular disease. Curr. Atheroscler. Rep. 6, 381–387 (2004).
   Google Scholar
• Liu JL, Sempos CT, Donahue RP et al.: Non-high-density lipoprotein and very-lowdensity lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am. J. Cardiol. 98, 1363–1368 (2006).
   Google Scholar
• Important new data on the risk associated with very low-density lipoproteincholesterol and non-high-density lipoprotein-cholesterol (HDL-C). Demonstrates that non-HDL-C values are unrelated to TG.
   Google Scholar
• Ridker PM, Rifai N, Cook NR et al.: Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in Women. JAMA 294, 326–333 (2005).
   Google Scholar
• Tanko LB, Bagger YZ, Qin G et al.: Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 111, 1883–1890 (2005).
   Google Scholar
• Castelli W: Epidemiology of triglycerides: a view from Framingham. Am. J. Cardiol. 70(Suppl), H3–H9 (1992).
   Google Scholar
• Classic but little known paper showing that the risk associated with TG in women begins at 100 mg/dl and plateaus at 250 mg/dl.
   Google Scholar
• Brewer HB: Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am. J. Cardiol. 83, F3–F12 (1999).
   Google Scholar
• Kolovou GD, Anagnostopoulou KK, Pilatis N et al.: Low fasting low high-density lipoprotein and postprandial lipemia. Lipids Health Dis. 3, 18 (2004).
   Google Scholar
• Hyson D, Rutledge JC, Berglund L: Postprandial lipemia and cardiovascular disease. Curr. Atheroscler. Rep. 5, 437–444 (2003).
   Google Scholar
• van Beek AP, de Ruijter-Heijstek FC, Erkelens DW et al.: Menopause is associated with reduced protection from postprandial lipemia. Arterioscler. Thromb. Vasc. Biol. 19, 2737– 2741 (1999).
   Google Scholar
• Criqui MH: Obesity, risk factors, and predicting cardiovascular events. Circulation 111, 1869–1870 (2005).
   Google Scholar
• Szapary PO, Rader DJ: The triglyceride–high-density lipoprotein axis: an important target of therapy? Am. Heart J. 148, 211–221 (2004).
   Google Scholar
• Excellent review of the topic.
   Google Scholar
• Mauriege P, Imbeault P, Prud-Homme D et al.: Subcutaneous adipose tissue metabolism at menopause: importance of body fatness and regional fat distribution. J. Clin. Endocrinol. Metab. 85, 2446–2454 (2000).
   Google Scholar
• Schneider JG, Tompkins C, Blumenthal RS, Moria SM: The metabolic syndrome in women. Cardiol. Rev. 14, 286–229 (2006).
   Google Scholar
• Poehlman ET, Toth MJ, Gardner AW: Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann. Intern. Med. 123, 673–675 (1995).
   Google Scholar
• Piche ME, Weisnage SJ, Corneau L et al.: Contribution of abdominal visceral obesity and insulin resistance to the cardiovascular risk profile of postmenopausal women. Diabetes 54, 770–777 (2005).
   Google Scholar
• Natarajan S, Liao Y, Cao G et al.: Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch. Int. Med. 163, 1735–1740 (2003).
   Google Scholar
• Huxley R, Barzi F, Woodward: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Br. Med. J. 332, 73–78 (2006).
   Google Scholar
• Rajaratnam RA, Gylling H, Miettinen TA: Independent association of serum squalene and noncholesterol sterols with coronary artery disease in postmenopausal women. J. Am. Coll. Cardiol. 35, 1185–1191 (2000).
   Google Scholar
• Miettinen TA, Gylling H, Strandberg T et al.: Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Br. Med. J. 316, 1127–1130 (1998).
   Google Scholar
• Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).
   Google Scholar
• Clearfield M, Downs JR, Weis S et al.: Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J. Womens Health Gend. Based Med. 10, 971–981 (2001).
   Google Scholar
• Bitner V, Simon J, Fong J et al.: Correlates of high HDL cholesterol among women with coronary heart disease. Am. Heart J. 139, 288–296 (2000).
   Google Scholar
• Yeh DD, Feeman MW Meigs JB et al.: Risk factors for coronary artery disease in patients with elevated high density lipoprotein cholesterol. Am. J. Cardiol. 99, 1–4 (2007).
   Google Scholar
• Ansell BJ, Watson KE, Fogelman AM et al.: High density HDL function recent advances. J. Am. Coll. Cardiol. 46, 1792–1798 (2005).
   Google Scholar
• Jenner JL, Ordovas JM, Lamon-Fava S et al.: Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 87, 35–1141 (1993).
   Google Scholar
• Suk Danik J, Rifai N, Buring JE, Ridker PM: Lipoprotein(a), measured with an assay independent of apolipoprotein (a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 296, 1363–1370 (2006).
   Google Scholar
• Very important new data which does not support measurement of lipoprotein(a) in most women.
   Google Scholar
• Ansell BJ, Fonarow GC, Maki KC et al.: Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am. Heart J. 152(5), 976–981 (2006).
   Google Scholar
• Wong ND, Lopez V, Tang S, Williams GR: Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am. J. Cardiol. 98, 204–208 (2006).
   Google Scholar
• Manson JE, Greenland P, LaCroix AZ et al.: Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N. Engl. J. Med. 347, 716–725 (2002).
   Google Scholar
• Downs JR, Clearfield M, Weiss S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 279, 1615–1622 (1998).
   Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. Heart Protection Study Collaborative Group. Lancet 360, 7–22 (2002).
   Google Scholar
• Sever PS, Dahlof B, Poulter NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361, 1149–1158 (2003).
   Google Scholar
• Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 357, 905–910 (2001).
   Google Scholar
• The FIELD Study Investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study); randomized controlled trial. Lancet 36(6), 1849–1861 (2005).
   Google Scholar
• Bittner V: Perspectives on dyslipidemia and coronary heart disease in women. J. Am. Coll. Cardiol. 46, 1628–1635 (2005).
   Google Scholar
• Very nice comprehensive review of the subject.
   Google Scholar
• Wenger NK: Lipid abnormalities in women. Cardiol. Rev. 14, 276–280 (2006).
   Google Scholar
• Bellasi A, Raggi P: Lipid-lowering therapy with statins in postmenopausal women: a few answered and many unanswered questions. Future Lipidol. 1, 375–379 (2006).
   Google Scholar
• Walsh JME, Pignone M: Drug treatment of hyperlipidemia in women. JAMA 291, 2243–2252 (2004).
   Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals; a randomized placebo-controlled trial. Lancet 351, 2005–2016 (2003).
   Google Scholar
• Trial that enrolled the most women.
   Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes; a randomized placebo-controlled trial. Lancet 361, 7–22 (2003).
   Google Scholar
• Wenger NK, Lewis SJ, Welty FK et al.: On behalf of the TNT Steering Committee and Investigators. Effect of 80 mg versus 10 mg of atorvastatin in women and men with stable coronary disease. Circulation 112(Suppl. II]), 819 (2005).
   Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al.: Intensive verus moderate lipid lowering with statin after acute coronary syndromes. N. Engl. J. Med. 350, 1495–1504 (2004).
   Google Scholar
• Raggi P, Davidson M, Callister TQ et al.: Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 112, 563–571 (2005).
   Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al.: Effect of intensive compare with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071–1080 (2004).
   Google Scholar
• Nissen SE, Nichols SJ, Sipahi I et al.: For the ASTEROID Investigators: Effect of very high-intensity statin therapy on the regression of coronary atherosclerosis. The ASTEROID Trial. JAMA 295, 1556–1565 (2006).
   Google Scholar
• Lewis SJ, Sacks, FM, Mitchell JS et al.: Effect of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events (CARE) Trial. J. Am. Coll. Cardiol. 32, 140–146 (1998).
   Google Scholar
• Lewis SJ, Sacks FM, Mitchell JS et al.: For the CARE Investigators: Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J. Am. Coll. Cardiol. 32, 140–146 (1998).
   Google Scholar
• Calhoun HM, Betteridge DJ, Durrington PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364(9435), 685–696 (2004).
   Google Scholar
• Sever PS, Dahlof B, Poulter NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo–Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOTT-LLA): a multicentre randomized controlled trial. Lancet 361, 1149–1158 (2003).
   Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al.: For the PROSPER Study Group: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360, 1623–1630 (2002).
   Google Scholar
• Knopp R, D’Emden M, Smilde JG et al.: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with Type 2 diabetes. Diabetes Care 1478–1485 (2006).
   Google Scholar
• Hague W, Forder P, Simes J et al.: Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary artery disease: results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Am. Heart J. 145(4), 643–651 (2003).
   Google Scholar
• Packard CJ, Ford I, Robertson M et al.: For the PROSPER Study Group: Plasma lipoproteins and apolipoprotein as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 112, 3058–3065 (2005).
   Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 288, 2998–3007 (2002).
   Google Scholar
• Sudhop T, Lutjohann D, Ratman C, von Bergmann J, von Bergmann K: Differences in the response of serum lipoproteins to fenofibrate between women and men with primary hypercholesterolemia. Eur. J. Clin. Pharmacol. 50, 365–369 (1996).
   Google Scholar
• Research Committee of the Scottish Society of Physicians. Ischemic heart disease: a secondary prevention trial using clofibrate. Br. Med. J. 4, 775–784 (1971).
   Google Scholar
• Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischemic heart disease. Br. Med. J. 4, 767–775 (1971).
   Google Scholar
• BIP Study Group. Secondary prevention by raising HDL-C and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 102, 21–27 (2000).
   Google Scholar
• Dorr AE, Gunderson K, Schnider JC, Spencer TW, Martin WB: Colestipol hydrochloride in hypercholesterolemic patient: effect on serum cholesterol and mortality. J. Chronic Dis. 31, 5–14 (1978).
   Google Scholar
• Ansell BJ, Fonarow GC, Navab M et al.: Modifying the anti-inflammatory effects of high-density lipoproteins. Curr. Atheroscler. Rep. 9, 57–63 (2007).
   Google Scholar
• Libby P, Sasiela W: Plaque stabilization: can we turn theory into evidence. Am. J. Cardiol. 98(Suppl), P26–P33 (2006).
   Google Scholar
• Grundy SM: Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat. Rev. Drug Discov. 5, 295–309 (2006).
   Google Scholar
• Istvan E: Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atherosclerosis 4, 3–8 (2003).
   Google Scholar
• Miettinen TA, Gylling H: Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur. J. Clin. Invest. 33, 976–982 (2003).
   Google Scholar
• Miettinen TA, Railo M, Lepäntalo M et al.: Plant sterols in serum and in atherosclerotic plaques of patients undergoing carotid endarterectomy. J. Am. Coll. Cardiol. 45, 1794–1801 (2005).
   Google Scholar
• Thought provoking study of the potential undesirable effect of statins.
   Google Scholar
• Sudhop T, Lütjohann D, Kodal A et al.: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106, 1943–1948 (2002).
   Google Scholar
• Patel SB: Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways. Curr. Cardiol. Rep. 6, 439–442 (2004).
   Google Scholar
• Davidson MH, Dittakavi V, Bandari A et al.: Colesevelam HCl decreases atherosclerosis and may activate reverse cholesterol transport in cholesterol-fed rabbits. J. Appl. Res. 6, 4–12 (2006).
   Google Scholar
• Espenshade PJ: SREBPs: sterol-regulated transcription factors. J. Cell Sci. 119, 973–976.
   Google Scholar
• Roberts W: Atherosclerosis: its cause and its prevention. Am. J. Cardiol. 98, 1550–1555 (2006).
   Google Scholar
• Malik S, Kashyap M: Niacin, lipids and heart disease. Curr. Cardiol. Rep. 5, 470–476 (2003).
   Google Scholar
• Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPAR- in energy metabolism and vascular homeostasis. J. Clin. Invest. 116, 571–580 (2006).
   Google Scholar
• Davidson MH: Mechanisms form the hypotriglyceridemic effects of marine omega-3 fatty acids. Am. J. Cardiol. 98(Suppl), I27–I33 (2006).
   Google Scholar
• Dayspring T, Pokrywka G: Fibrate therapy in patients with metabolic syndrome and diabetes mellitus. Curr. Atheroscler. Rep. 8, 356–364 (2006).
   Google Scholar
• Martin G, Duez H, Blanquart C et al.: Statininduced inhibition of the Rho-signaling pathway activates PPAR and induces HDL apoA-I. J. Clin. Invest. 7, 1423–1432 (2001).
   Google Scholar
• Schoonjans K, Peinado-Onsurbe J, Fruchart JC et al.: 3-hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 452, 160–164 (1999).
   Google Scholar
• Suzukawa M, Abbey M, Howe PRC, Nestel PJ: Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J. Lipid Res. 36, 473–484 (1995).
   Google Scholar
• Packard CJ: Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr. Opin. Lipidol. 17, 412–417 (2006).
   Google Scholar
• Farnier M, Freeman M, Macdonell G et al.: Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26, 897–905 (2005).
   Google Scholar
• Arakawa R, Tamehiro N, Nishimaki-Mogami T et al.: Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I–mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor–dependent manner. Arterioscler. Thromb. Vasc. Biol. 25, 1193–1197 (2005).
   Google Scholar
• Chinetti-Gbaguidi, Rigamonti E, Helin L et al.: Peroxisome proliferator-activated receptor- controls cellular cholesterol trafficking in macrophages. J. Lipid Res. 46, 2717–2725 (2005).
   Google Scholar
• Rubic T, Trottmann M, Lorenz RL: Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmacol. 67, 411–419 (2004).
   Google Scholar
• Wysocki J, Belowski D, Kalina M et al.: Effects of micronized fenofibrate on insulin resistance in patients with the metabolic syndrome. Int. J. Clin. Pharmacol. Ther. 42, 212–217 (2004).
   Google Scholar
• Sheu WHH, Shieh SM, Shen DDC et al.: Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia. Am. Heart J. 127, 331–336 (1994).
   Google Scholar
• Davidson MH: Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am. J. Cardiol. 96(Suppl), K3–K13 (2005).
   Google Scholar
• Excellent review making the case for more aggressive combination lipid therapies.
   Google Scholar
• Napoli C, Lerman L, de Nigris F et al.: Rethinking primary prevention of atherosclerosis-related diseases. Circulation 114, 2517–2527 (2006).
   Google Scholar
• Miettinen TA, Pyorala K, Olsson AG et al.: Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 96, 4211–4218 (1997).
   Google Scholar